Project Grant K08CA308788
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $275K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $738,698 on August 12, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the molecular and genomic basis of transposon-associated alternative splicing (TEAS) in human cancers. The research integrates genomic, transcriptomic, and functional analyses across three aims. The first comprehensively characterizes TEAS events using bulk and single-cell long-read RNA...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $516,458 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant R01HL187595. The funded research investigates mechanisms of somatic rescue in Fanconi Anemia, a prototypical inherited bone marrow failure syndrome characterized by deficiency in DNA interstrand crosslink repair. The project examines how some...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $350,860 on September 1, 2026, through a Cooperative Agreement (UH2CA312695) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to implement exome capture-based RNA sequencing for real-time clinical risk stratification in pediatric B-cell acute lymphoblastic leukemia (B-ALL) treatment. The recipient will establish centralized diagnostic RNA sequencing-based molecular classification across three...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute $276,545 on June 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop genomic risk prediction models for T-cell malignancies. The recipient will identify high-risk genomic features associated with relapse and death in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) stratified by genetic ancestry, then develop and validate risk prediction...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Baylor College of Medicine $321,000 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize germline and somatic genetic variants in Langerhans cell histiocytosis pathogenesis. The research investigates inherited and acquired genetic factors contributing to LCH risk and adverse outcomes. LCH is an inflammatory myeloid neoplasia characterized by pathogenic...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- The National Cancer Institute awarded Boston Children's Hospital $578,559 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tumor suppressor function of P190 RhoGAP and identify therapeutic vulnerabilities in cancer cells with ARHGAP35 alterations. The research examines how the P190A protein suppresses tumor formation through effects on autophagy and the Hippo signaling pathway. Aim 1 characterizes autophagy defects in cancer cells lacking functional...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $235,491 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer research. The award funds investigation into high-count monoclonal B-cell lymphocytosis (HC-MBL) and its relationship to mosaic chromosomal alterations, particularly deletions in chromosome 13q and trisomy 12. The research will examine phenotypic consequences of HC-MBL across two...
- The National Cancer Institute awarded The Children's Hospital Of Philadelphia $744,511 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias and identify therapeutic vulnerabilities in these treatment-resistant leukemic populations. The research investigates molecular characteristics and clinical implications of HSPC-like blasts across major high-risk leukemia...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $522,196 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate non-canonical BRAF mutations in acute myeloid leukemia development and therapeutic response. The recipient will conduct research to delineate how BRAF mutations contribute to leukemogenesis, disease phenotype, and therapeutic resistance in AML patients who exhibit dismal survival outcomes regardless of treatment...